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Abstract

Tumor-associated macrophages (TAMs) affect cancer progression and therapy. Ovarian carcinoma
often metastasizes to the peritoneal cavity. Here, we found two peritoneal macrophage subsets in
mice bearing ID8 ovarian cancer based on the Tim-4 (T-cell immunoglobulin and mucin domain
containing 4) expression. Tim-4+ TAMs were embryonically originated and locally sustained while Tim4- TAMs were replenished from circulating monocytes. Tim-4+ TAMs, but not Tim-4- TAMs, promoted
tumor growth in vivo. Relative to Tim-4- TAMs, Tim-4+ TAMs manifested high oxidative
phosphorylation and adapted mitophagy to alleviate oxidative stress. High levels of arginase-1 in Tim4+ TAMs contributed to potent mitophagy activities via weakened mTORC1 activation due to low
arginine resultant from arginase-1-mediated metabolism. Furthermore, genetic deficiency of
autophagy element FIP200 resulted in Tim-4+ TAM loss via ROS-mediated apoptosis, and elevated T
cell-immunity and ID8 tumor inhibition in vivo. Moreover, human ovarian cancer-associated CRIg
(complement receptor of the Immunoglobulin superfamily) positive macrophages were
transcriptionally, metabolically, and functionally similar to murine Tim-4+ TAMs. Thus, targeting CRIg+
Tim-4+) TAMs may potentially treat ovarian cancer patients with peritoneal metastasis.

(
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Introduction

Ovarian cancer frequently metastasizes to the peritoneal cavity as manifested by ascites fluid
formation and a large number of tumor islets distributing to the peritoneum, omentum, and serosal
surfaces of the viscera. The entire peritoneal cavity becomes an active tumor microenvironment,
supporting ovarian cancer metastasis and progression (1). TAMs constitute over 50% of cells in the
peritoneal tumor implants and the ascites fluids in patients with peritoneal ovarian cancer metastasis.
Macrophages are physiologically critical mediators of tissue homeostasis. However, TAMs can directly
support tumor growth and suppress the tumor immune responses (2-4). In line with this, previous
studies in mouse models have shown that peritoneal TAMs generally promoted ovarian cancer
metastasis and inhibited immunity (5-7). These observations suggest that TAMs may be an ideal
target for cancer immunotherapy (3). Following this thought, different approaches - including targeting
TAM trafficking, switching their functions, and developing TAM-depleting antibody - have been tested
in preclinical models (8). However, these approaches have failed successful clinical translation (9-11).
Furthermore, macrophages can uptake, process, and present antigens to T cells and promote antitumor immunity. Macrophages may directly mediate tumor killing and are associated with improved
patient outcome in some types of cancer (12-14). In addition, emerging evidence indicates that
monocytes are not the sole and major source of tissue macrophages, and embryonic derived
macrophages can form a distinct tissue macrophage subset (15, 16). It seems that embryonic derived
macrophages and peripheral monocyte-derived macrophages may play different, and often conflicting
roles in different types of tumor models (17-19). Therefore, the controversies among the previous
studies beg an in-depth understanding of TAM ontogeny, phenotype, metabolism, and functional
characteristics in vitro and in vivo, which is critical for eventually developing effective mechanisminformed TAM-targeted cancer immunotherapy.
3

In this work, we focus on peritoneal residential macrophages in ovarian cancer models and patients
with ovarian cancer. Previous studies have implicated that peritoneal residential macrophages may be
distinguished from other tissue residential macrophages in gene profile and function (20-22). Notably,
the majority of these studies are realized in steady state and inflammatory disease models (23, 24).
TAM subsets remain poorly understood in ovarian cancer peritoneal metastasis and progression (25).
Based on the relative expression levels of F4/80 and MHC-II, previous studies have classified
macrophages into 2 subsets, F4/80HighMHC-IILow and F4/80LowMHC-IIHigh (5, 26). Here, based on Tim-4
expression, we identified two phenotypically, transcriptionally, ontogenically, metabolically, and
functionally distinct TAM subsets, Tim-4+ and Tim-4- TAMs in ovarian cancer peritoneal metastasis
model, and extended our studies to patients with ovarian cancer.
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Results

Tim-4 defines two distinct peritoneal macrophage subsets in ovarian cancer. Ovarian carcinoma often
metastasizes to the peritoneal cavity. However, peritoneal residential macrophages are poorly
understood in ovarian cancer. To explore the nature of peritoneal TAMs in ovarian cancer, we
established ID8 ovarian cancers in the mouse peritoneal cavity and studied TAMs in the peritoneal
ascites fluids. Flow cytometry identified CD45+CD11b+CD90-B220-Gr1- macrophages in the peritoneal
cavity in ID8 bearing mice (Supplemental Figure 1A). These cells expressed multiple macrophage
markers, including CD68, CD206, colony stimulating factor 1 receptor (CSF1R, or CD115), and
MerTK, but not Siglec-F, a marker for eosinophils and alveolar macrophages (Figure 1A). The levels
of TAMs increased following tumor progression (Figure 1B).

Tim-4 is a marker for embryonic-derived residential macrophages in intestine (27, 28), skin (29), and
heart (30). Interestingly, based on Tim-4 expression, we observed 2 distinct peritoneal TAMs: Tim-4+
and Tim-4- cells (Figure 1C). To explore if Tim-4+ and Tim-4- peritoneal TAMs were phenotypically
different populations, we compared the expression of a panel of macrophage-associated markers on
Tim-4+ and Tim-4- peritoneal TAMs (Figure 1D). We noticed that Tim-4+ TAMs represented the
majority of F4/80HighMHC-IILow subset while Tim-4- TAMs represented the majority of F4/80LowMHCIIHigh subset (Figure 1D and Supplemental Figure 1B). In addition, Tim-4+ and Tim-4- TAMs expressed
comparable levels of CD206, PD-L1, and MerTK (Supplemental Figure 1C). Long-lived peritoneal
residential macrophages selectively express transcriptional factor GATA6 and its down-stream genes
(20-22). We found that GATA6 was enriched in Tim-4+ TAMs, but not Tim-4- TAMs (Figure 1D).
Furthermore, Tim-4+ TAMs expressed high levels of several GATA6-down-stream genes - including
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Aspa, Cd5l, Nt5e, Ltbp1, and Tgfb2 - as compared with Tim-4- TAMs (20, 22) (Supplemental Figure
1D).

To gain a comprehensive insight into the differences between Tim-4+ and Tim-4- TAMs, we performed
transcriptional profiling on the paired Tim-4+ and Tim-4- TAM subsets isolated from ID8 tumor bearing
mice. Among 1037 differentially expressed genes in the paired Tim-4+ and Tim-4- TAM subsets, 267
and 770 genes were up-regulated and down-regulated, respectively, in Tim-4+ TAMs as compared
with Tim-4- TAMs (Figure 1E). The top up-regulated genes, including Lyz1, Vsig4, and Wnt2, were
linked to F4/80HighMHC-II- residential macrophages (31), while the top down-regulated genes,
including Ccr2, Cd226, and Plxnd1, were associated with MHC-IIHigh monocyte-derived macrophages
(Supplementary Table 1) (32). Gene Set Enrichment Analysis (GSEA) revealed an enriched
F4/80HighMHC-II- residential macrophage gene signature (Figure 1F) (31) and a weak MHC-II+
monocyte-derived macrophage gene signature (Figure 1G) (32) in Tim-4+ TAMs as compared with
Tim-4- TAMs. Together, the data suggest that Tim-4 identifies two phenotypically distinct peritoneal
macrophage subsets in ovarian cancer. We next tested whether Tim-4+ and Tim-4- peritoneal TAMs
are ontogenically, metabolically, and functionally distinct subsets.

Tim-4- TAMs migrate from peripheral monocytes without affecting tumor growth. Based on our
phenotypic and transcriptional profile on Tim-4+ and Tim-4- TAMs, we hypothesized that Tim-4+ TAMs
were embryonically derived residential macrophages and Tim-4- TAMs were replenished from blood
monocytes. In healthy mice (tumor free), Tim-4+ and Tim-4- peritoneal macrophages respectively
accounted for 85% and 15% of peritoneal macrophages in homeostasis (Supplemental Figure 2, A
and B). After tumor inoculation, absolute numbers of Tim-4+ (Figure 2A) and Tim-4- (Figure 2B) TAMs
increased following tumor progression. Interestingly, the percentage of Tim-4+ TAMs in TAMs
6

gradually shrank (Supplemental Figure 2A) while the percentage of Tim-4- TAMs in TAMs moderately
increased (Supplemental Figure 2B). Six to 8 weeks after tumor inoculation, there were approximately
50% each of Tim-4+ (Figure 2A) and Tim-4- (Figure 2B) TAMs in mice.

Next, we explored the origin of Tim-4+ and Tim-4- TAMs in 3 confirmatory settings. CCR2 mediates
peripheral monocyte trafficking into the peritoneal cavity (32, 33). The first experimental setting was a
pharmacological depletion model. We treated adult mice with sc-202525, a CCR2 antagonist, for two
weeks. Treatment with sc-202525 resulted in reduced F4/80LowMHC-IIHigh peritoneal macrophages and
had no effect on F4/80HighMHC-IILow macrophage (Supplemental Figure 2C) (33). Then, we inoculated
ID8 tumor cells into the peritoneal cavity in these pre-treated mice, and treated them with sc-202525
continually for 6 weeks. We found comparable tumor volume (Figure 2C) and a similar quantity of Tim4+ TAMs (Figure 2D) in mice receiving PBS and CCR2 antagonist. This data suggests that blockade
of monocyte peritoneal trafficking has no obvious effect on Tim-4+ TAMs and ID8 tumor growth.

The second experimental setting was a genetic model. We compared peritoneal macrophages in
CCR2 deficient (Ccr2-/-) and proficient (Ccr2+/+) mice. We observed a similar number of total peritoneal
macrophages in tumor-free Ccr2-/- and Ccr2+/+ mice (Supplemental Figure 2D). However, the
percentage (Supplemental Figure 2E) and absolute number (Supplemental Figure 2F) of Tim-4-, but
not Tim-4+, peritoneal macrophages were reduced in Ccr2-/- mice. We inoculated ID8 tumor cells into
the peritoneal cavity of Ccr2+/+ and Ccr2-/- mice. Again, we observed similar tumor growth (Figure 2E)
in Ccr2-/- and Ccr2+/+ mice. As expected, Tim-4- TAMs remained limited in Ccr2-/- tumor bearing mice
as compared with Ccr2+/+ mice (Figure 2, F and G). This data suggests that monocyte trafficking
deficiency has no obvious effect on ID8 tumor growth.
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The third experimental setting was an adoptive immune cell transfusion system. We explored whether
Tim-4+ TAMs could be directly differentiated from monocytes in the tumor microenvironment. We
injected CD45.1+ monocytes into ID8 tumor bearing cognate CD45.2 mice. Three days later, we
observed that CD45.1+ donor TAMs were in F4/80LowMHC-IIHigh population (Supplemental Figure 2G)
and expressed no Tim-4 (Figure 2H). Together, these data suggest that circulating monocytes are a
cellular source for Tim-4- TAMs, and Tim-4+ TAMs may be embryonic residential macrophages.

Tim-4+ TAMs are embryonically derived proliferative cells with pro-tumor function. Both Tim-4+ and
Tim-4- TAMs were increased following tumor progression. Tim-4- TAMs were from peripheral
monocytes. We hypothesized that increased Tim-4+ TAM numbers are attributed to their local selfexpansion in the tumor microenvironment. To test this, we compared the proliferative capacity of Tim4+ macrophages in normal and tumor bearing mice (21, 34). As expected, Tim-4+ TAMs exhibited
increased cell proliferation as shown by more TAMs in the SG2M phase, when compared with normal
Tim-4+ residential macrophages (Figure 3, A and B). As a confirmation, we injected 5-bromo-2’deoxyuridine (BrdU) into the peritoneal cavity in tumor bearing mice for 3 hours and observed
increased BrdU+ Tim-4+ TAMs (Supplemental Figure 3, A and B). Accompanied with this, we detected
elevated expression of cell-cycle regulator transcripts (Supplemental Figure 3C) and proteins (Figure
3C). Thus, Tim-4+ TAMs are locally proliferative residential macrophages.

As there is no direct approach to specifically manipulate Tim-4+ residential macrophages in vivo, we
applied two complementary models to explore a potential role of Tim-4+ TAM in tumor growth. In the
first model, we mixed ID8 tumor cells and Tim-4+ TAMs isolated from ID8-bearing mice and inoculated
wild type mice with the mixture. We found that addition of Tim-4+ TAMs promoted tumor growth
(Supplemental Figure 3D). In the second model, we used a modified method to deplete Tim-4+
8

macrophages with clodronate-liposomes (CL) (6, 19). We initially treated normal mice with one dose
of CL, followed by a 14-day chase period to allow mice to recover circulating monocyte (Supplemental
Figure 3E). We found that circulating monocyte numbers were similar in CL-treated and control mice
at 14-days following CL treatment (Supplemental Figure 3F), and the levels of Tim-4+ macrophages
were significantly lower in CL-treated mice than control mice (Figure 3D). Then, we peritoneally
inoculated these mice with ID8 tumor cells. Under this condition, we observed a slower tumor growth
in CL-treated mice as compared with control mice (Figure 3E). On day 42, the percentage of Tim-4+
TAMs remained lower in CL-treated mice than control mice, while the percentage of Tim-4- TAMs
were comparable in the CL-treated mice and control mice (Figure 3F). Furthermore, the number of
Tim-4+ TAMs positively correlated with tumor volume in tumor bearing mice (Figure 3G). Altogether,
the data suggest that Tim-4+ TAMs are embryonically derived proliferative cells and promote tumor
growth.

Tim-4+ TAMs exhibit and maintain high mitochondria activity and mitophagy function. Metabolism
affects immune cell phenotype and function in the tumor microenvironment (35). Elevated oxidative
phosphorylation is observed in ID8 and B16 tumor associated peritoneal macrophages as compared
with normal peritoneal macrophage in mice (6). Given that Tim-4+ and Tim-4- TAMs are phenotypically
and functionally different, we hypothesized that peritoneal TAM subsets may present different
mitochondria activities. To test this, we carried out the Seahorse experiments to assess and compared
the functional profile of mitochondria in Tim-4+ and Tim-4- TAMs. TAMs were treated with oligomycin
(an adenosine triphosphate (ATP) synthase inhibitor), cyanide p-trifluoromethoxyphenyl-hydrazone
(FCCP) (H+ ionophore), and rotenone plus antimycin A (inhibitors of the electron-transport chain)
(Figure 4A). We observed higher levels of basal and maximal respiration (Figure 4A) in Tim-4+ TAMs
than Tim-4- TAMs, as shown by the rate of O2 consumption (OCR). After normalizing the OCR values
9

to baseline, Tim-4+ TAMs remained to exhibit an elevated maximal respiration as compared to Tim-4TAMs (Figure 4B). The data suggests that Tim-4+ TAMs manifest high mitochondria activity. In line
with this, we observed higher levels of mitochondria related reactive oxygen species (Figure 4C) in
Tim-4+ TAMs compared with Tim-4- TAMs. In further support of this, the mitochondrial genome
encoded oxidative-phosphorylation related genes were highly enriched in Tim-4+ TAMs, but not Tim-4TAMs (Figure 4D). MitoTracker Green staining showed enhanced mitochondrial mass in Tim-4+ TAMs
compared with Tim-4- TAMs (Figure 4E). Western blot revealed elevated expression of mitochondria
related proteins, COX IV and SDHB, in Tim-4+ TAMs compared with Tim-4- TAMs (Supplemental
Figure 4A).

Oxidative stress is a bystander-metabolic feature associated with oxidative phosphorylation
(OXPHOS). Dendritic cells (36) and regulatory T cells (37), are phenotypically and functionally altered
by oxidative stress in the tumor microenvironment. Autophagy alleviates oxidative stress by
eliminating damaged mitochondria and reactive oxygen species (ROS) in a process called mitophagy
(38). To investigate if autophagy activity was different in TAM subsets in response to high OXPHOS,
we treated macrophages with chloroquine (CQ), an autophagy inhibitor, to prevent autophagosome
degradation. Flow cytometry analysis revealed an increased LC-3II density in autophagosomes in
Tim-4+ TAMs compared with Tim-4- TAMs (Figure 4F). Western blot demonstrated a high conversion
of LC-3I to LC-3II in Tim-4+ TAMs compared with Tim-4- TAMs (Supplemental Figure 4B). To evaluate
the effect of autophagy on mitochondria fitness in Tim-4+ and Tim-4- TAMs, we treated TAMs with CQ
for 24 hours and detected damaged mitochondria accumulation via a combination of MitoTracker
Green (membrane potential (ΔΨm) independent mitochondrial stain) and MitoTracker Deep Red
(ΔΨm dependent mitochondrial stain) (39). As expected, treatment with CQ caused more
accumulation of damaged mitochondria (MitoTracker Greenhigh, MitoTracker Deep Redlow) in Tim-4+
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TAMs compared with that in Tim-4- TAMs (Figure 4G). The data suggest that Tim-4+ TAMs highly rely
on mitophagy to maintain mitochondrial fitness in the tumor microenvironment.

Arginase-1 impacts mitochondria fitness and mitophagy via mTORC1 in Tim-4+ TAMs. We next
examined the mechanism by which Tim-4+ TAMs exhibited high mitophagy activity. GSEA revealed no
enrichment of mitophagy-related genes in Tim-4+ TAMs compared with Tim-4- TAMs (Supplemental
Figure 5A). It suggests that mitophagy-related autophagy genes may be regulated at posttranscriptional levels in Tim-4+ and Tim-4- TAMs. Unc-51-like kinase 1 (ULK1) phosphorylation at
Ser757 by mammalian target of rapamycin complex 1 (mTORC1) competes with phosphorylation at
Ser317 by AMP-activated protein kinase (AMPK) to inhibit the initiation of
canonical autophagy pathway (40). As compared to Tim-4- TAMs, we detected lower levels of ULK1
phosphorylation at Ser757 and similar levels of ULK1 phosphorylation at Ser317 in Tim-4+ TAMs
(Figure 5A). We suspected that mTORC1 activity may be reduced in Tim-4+ TAMs. As expected, Tim4+ TAMs manifested a weak mTORC1 activity as compared to Tim-4+ TAMs, as shown by low levels
of phosphorylation of S6 kinase (p-S6K) (Figure 5A), a well-characterized mTORC1 substrate (41).
Amino acid sensing may determine mTORC1 activation (42). We explored a potential role of amino
acids on mTORC1 activity in TAM subsets. We cultured TAM subsets in amino acid-free medium and
observed a potent inhibition of mTORC1 activation in both Tim-4+ and Tim-4- TAMs. Interestingly,
supplementation of amino acids induced a robust mTORC1 activation in Tim-4- TAMs, but not in Tim4+ TAMs (Figure 5B). Intracellular arginine can sustain mTORC1 activation in regulatory T cells (43).
To evaluate if arginine is involved in maintaining mTORC1 activation in Tim-4+ TAMs, we treated Tim4+ TAMs with different concentrations of arginine. As expected, exogenous arginine could induce and
maintain mTORC1 activation in Tim-4+ TAMs (Figure 5C). Thus, arginine, as a key amino acid, might
define different mTORC1 activities in Tim-4+ and Tim-4- TAMs.
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Intracellular arginine is controlled by arginine uptake and metabolism. We detected comparable levels
of arginine uptake in Tim-4+ TAMs and Tim-4- TAMs (Supplemental Figure 5B). Arginase-1 converts
intracellular arginine to downstream metabolites including ornithine and urea. Western blot revealed
high levels of arginase-1 in total TAMs compared to normal peritoneal macrophage (Supplemental
Figure 5C) (44). RNA sequencing data showed high levels of arginase-1 transcripts in Tim-4+ TAMs
compared to Tim-4- TAMs (Supplemental Figure 5D), and comparable expression levels of other
genes in polyamine biogenesis, including Odc1 and Srm, in Tim-4- and Tim-4+ TAMs (Supplemental
Figure 5D). In line with this, flow cytometry analysis (Figure 5D) and Western blot (Supplemental
Figure 5E) demonstrated superior levels of arginase-1 protein in Tim-4+ TAMs compared to Tim-4TAMs. Notably, arginase-2 was not detectable in both TAM subsets (Supplemental Figure 5E). In
addition, we detected higher levels of arginase activity in Tim-4+ TAMs than that in Tim-4- TAMs
(Figure 5E). Then, we treated Tim-4+ TAMs with nor-NOHA, an arginase activity inhibitor, to block the
arginine consumption. We observed that nor-NOHA stimulated mTORC1 activation in Tim-4+ TAMs
(Figure 5F). Hence, weak mTORC1 activation may be attributed to high levels of arginase-1 and low
levels of intracellular arginine in Tim-4+ TAMs. To further elucidate a role of arginine in mitochondrial
fitness and mitophagy in Tim-4+ TAMs, we treated Tim-4+ TAMs with a combination of mitochondrial
inhibitors oligomycin and antimycin A, which collapse membrane potential (ΔΨm) (45), in the
presence of arginine or nor-NOHA. Oligomycin and antimycin A combination increased damaged
mitochondria in Tim-4+ TAMs (Supplemental Figure 5F). Interestingly, treatment with arginine or norNOHA resulted in an increase in damaged mitochondria in Tim-4+ TAMs and this effect was abolished
with rapamycin (Figure 5G). The data suggest that intracellular arginine mediates mitophagy inhibition
via mTORC1 activity in Tim-4+ TAMs. Thus, arginase-1 fine-tunes mitochondria fitness and mitophagy
in Tim-4+ TAMs.
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Autophagy deficiency results in loss of Tim-4+ TAMs in ovarian cancer. Mitophagy degrades damaged
mitochondria and removes ROS to prevent macrophage death (46). High levels of mitophagy in Tim4+ TAMs might be important to support their survival in the tumor microenvironment. To test this
possibility in vivo, we established ID8 tumor mouse models with autophagy deficiency in
macrophages. FIP200 (FAK-family interacting protein of 200 kDa) is one component of the ULK1Atg13-FIP200-Atg101 complex and is essential for the induction of mammalian autophagy (47). We
crossed mice with transgenic expression of Cre recombinase from the Lysozome promoter with loxPflanked FIP200 alleles (Fip200flox/flox) mice and deleted the loxP-flanked FIP200 alleles specifically in
myeloid cells (called ‘Fip200-/-’ here). Western blot showed a specific loss of FIP200 and an increase
in autophagy receptor p62 in macrophages isolated from the peritoneal cavity and differentiated from
bone marrow of Fip200-/- mice (Supplemental Figure 6A). We inoculated Fip200-/- mice with ID8 tumor
cells and detected high levels of damaged mitochondria accumulated in Tim-4+ Fip200-/- TAMs but not
in Tim-4- Fip200-/- TAMs compared to their wild type counterparts. The data additionally support the
notion that Tim-4+ TAMs, but not Tim-4- TAMs, relied on mitophagy in the tumor microenvironment in
vivo (Figure 6A). To functionally understand if mitophagy is important to Tim-4+ TAMs survival, we
analyzed the impact of autophagy deficiency in TAM numbers and phenotype in tumor bearing mice.
We found that the percentage (Figure 6B) and number (Figure 6C) of total TAMs was decreased in
Fip200-/- mice as compared with control mice. Interestingly, we observed a loss of Tim-4+ TAMs, but
not Tim-4- TAMs, in ID8 bearing Fip200-/- mice compared with the wild type mice, as shown by the
percentage (Figure 6D) and absolute number (Figure 6E) of Tim-4+ and Tim-4- TAMs. To explore
whether loss of Tim-4+ TAMs is attributed to the tumor microenvironment, we analyzed peritoneal
residential macrophage subsets in tumor free mice. We found comparable numbers of Tim-4+
residential macrophages in wild type and Fip200-/- mice (Supplemental Figure 6B). The results
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suggest that loss of Tim-4+ TAMs in Fip200-/- mice is related to tumor challenge.

Tim-4+ macrophages are of embryonic origin. Tim-4+ TAM pool may be determined by the balance
between self-expansion and survival. Interestingly, we observed an increase in SG2M percentage in
Tim-4+ TAMs in Fip200-/- mice compared with wild type mice. This indicates that loss of Tim-4+ TAMs
is unlikely due to a proliferative defect (Supplemental Figure 6C). T cell survival is impaired in the
tumor microenvironment due to metabolic challenge (48, 49). We analyzed TAM death and survival.
We observed increased Annexin V (Figure 6F) and cleaved Caspase 3 expression (Supplemental
Figure 6D) in Fip200-/- Tim-4+ TAMs as compared with wild type cells. To understand if cell death is
associated with intrinsic factor, we isolated CD45.2+Tim-4+ residential macrophages from Fip200-/mice and injected them into the peritoneal cavity in wild type CD45.1+ mice, and inoculated these mice
with ID8 cells. We found 3 to 5 folds more apoptosis in Fip200 deficient CD45.2+Tim-4+ TAMs
compared with wild type CD45.1+Tim-4+ TAMs (Figure 6G and Supplemental Figure 6E). These data
suggest that Fip200 deficiency results in Tim-4+ TAMs death in the tumor microenvironment.

GATA6 may control peritoneal residential macrophage development and survival (20-22). We
questioned if autophagy deficiency downregulated GATA6 expression in Tim-4+ TAMs and affected
their development in tumor. Expression of GATA6 and downstream genes was similar in wild type and
Tim-4+ Fip200-/- TAMs (Supplemental Figure 6F). Given that damaged mitochondria accumulated in
Tim-4+ TAMs in Fip200-/- mice compared with wild type mice (Figure 6A), we hypothesized increased
mitochondria related ROS may be responsible for Tim-4+ TAM death. Indeed, we observed increased
mitochondria related ROS (Figure 6H) and DNA damage marker pH2A.X (Supplemental Figure 6G) in
Tim-4+ TAMs from Fip200-/- mice compared with wild type mice. In addition, we treated the Fip200-/tumor bearing mice with ROS scavenger N-acetylcysteine (NAC) and analyzed Tim-4+ TAM
14

apoptosis. NAC treatment improved survival of autophagy deficient Tim-4+ TAMs (Figure 6I). To
further understand if mitophagy supports TAMs survival by eliminating ROS in the tumor
microenvironment, we compared the levels of cell apoptosis and ROS production between Tim-4+
Fip200-/- TAMs and Tim-4- Fip200-/- TAMs since they showed different levels of damaged mitochondria
accumulation (Figure 6A). We found a dramatic increase of apoptosis in Fip200 deficient Tim-4+ TAMs
as compared with Fip200 deficient Tim-4- TAMs (Figure 6J). In line with this, ROS accumulation was
elevated in Tim-4+ Fip200-/- TAMs, but not in Tim-4- Fip200-/- TAMs (Figure 6K). Thus, autophagy
deficiency causes a loss of Tim-4+ TAMs via accumulated ROS in the ovarian cancer
microenvironment.

Autophagy deficiency in macrophages supports T cell-mediated anti-tumor immunity. Given Tim-4+
TAMs, but not Tim-4- TAMs, contributed to ovarian cancer growth (Figure 2 and 3), we study whether
loss of Tim-4+ TAMs affects ovarian cancer progression in autophagy deficient mouse. We found that
FIP200 deficiency in macrophages slowed down tumor growth compared with wild type mice (Figure
7A). In addition, we inoculated MC38 colon cancer cells into the peritoneal cavity of Fip200-/- mice.
Again, FIP200 deficiency in myeloid cells resulted in a slower tumor growth compared with wild type
mice (Supplemental Figure 7A). Furthermore, we analyzed T cell phenotype and cytokine profile in
ID8 models. We detected an increase in the percentage of tumor infiltrating CD90+ T cells (Figure 7B)
and Ki67+ T cells (Figure 7C) in Fip200-/- mice compared with wild type mice. Furthermore, we
detected higher levels of IFNγ (Figure 7D) and TNFα (Figure 7E) expression in tumor infiltrating CD4
and CD8 T cells in Fip200-/- mice tumor bearing mice compared with wild-type tumor bearing mice.
Thus, autophagy deficiency in macrophages supports T cell-mediated anti-tumor immunity and slowed
down tumor progression.
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CRIg+ TAMs are the human counterparts of murine Tim-4+ TAMs in ovarian cancer. In an effort to find
the human equivalent of mouse Tim-4+ TAMs, we examined Tim-4 expression in TAMs in patients
with ovarian cancer. Flow cytometry analysis identified CD45+CD3-CD14+ TAMs in primary ovarian
tumor tissues, metastatic omentum, and ascites fluids in patients. We detected 3% of Tim-4+ TAMs
with a commercially available monoclonal anti-human Tim-4 antibody in the human ovarian cancer
microenvironment (Supplemental Figure 8A). The data suggests two possibilities: This anti-human
Tim-4 clone may not be sensitive to detect membrane Tim-4 on human residential TAMs in ovarian
cancer. Or, Tim-4 may not be an operational marker for human residential TAMs in ovarian cancer. To
explore potential markers for human ovarian cancer residential TAMs with similar features to mouse
Tim-4+ TAMs, we assessed genes encoding transmembrane receptors in mouse Tim-4+ TAMs. Vsig4
was among the most enriched genes in mouse Tim-4+ TAMs compared with Tim-4- TAMs (Figure 1E).
Vsig4 encodes a v-set and immunoglobulin-domain containing protein that is also known as a
complement receptor of the Immunoglobulin superfamily (CRIg) (50). We found that the vast majority
of CRIg+ TAMs were Tim-4+ TAMs in ID8 tumor bearing mice (Supplemental Figure 8B). FACS
analysis identified CRIg+ TAMs in patients with ovarian cancer (Supplemental Figure 8C). In addition,
VSIG4 transcripts were highly correlated with the expression of the alternative macrophage marker
CD163 in human ovarian cancer (Supplemental Figure 8D) (51). In line with our FACS data, TAMs
highly expressed VSIG4 transcripts in human ovarian cancer (25). We wondered if human CRIg+
TAMs could share genetic and biological features of mouse Tim-4+ TAMs. We first compared human
ovarian TAM transcriptomes with established signature of mouse Tim-4+ and Tim-4- TAMs (Figure 1E)
by using the connectivity MAP (cMAP) (52), which generates scores (as scaled dimensionless
quantities) indicative of the degree of “closeness” of one cell subset to a defined signature gene set.
Based on VSIG4 transcript levels from the RNA-Seq data in human ovarian cancer TAMs (25), cMAP
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analysis revealed that VSIG4High and VSIG4Low human TAMs aligned closely with the gene expression
patterns of mouse Tim-4+ and Tim-4- TAMs, respectively (Supplemental Figure 8E). In addition,
principal-component analysis (PCA) could segregate the transcriptomic profiles of VSIG4High TAMs
from VSIG4Low TAMs (Figure 8A). It is reported that CRIgHigh macrophages may represent peritoneal
residential macrophages in human as compared with CRIgLow macrophages (53). In line with this,
GSEA revealed that CRIgHigh peritoneal macrophages shared enriched up-regulated genes (Figure
8B) and down-regulated genes (Figure 8C) with VSIG4High TAMs (53). Furthermore, VSIG4High TAMs
expressed enriched genes for lysosome organization and formation (Supplemental Figure 8F), while
VSIG4Low TAMs were highly enriched genes for inflammatory response (Supplemental Figure 8G).
The data suggests that, at the transcriptional levels, VSIG4High TAMs represent CRIgHigh residential
macrophages in human ovarian cancer ascites.

To additionally characterize VSIG4High TAMs in human ovarian cancer, we used the Functional
Annotation Clustering tool in Enrichr to identify significantly enriched pathways and gene ontologies in
VSIG4High TAMs. Based on the significantly up-regulated genes, metabolic pathways and
mitochondria activity were strongly enriched in VSIG4High TAMs as compared with VSIG4Low TAMs
(Figure 8D). Particularly, VSIG4High TAMs were enriched with oxidative phosphorylation gene set
compared with VSIG4Low TAMs (Figure 8E). The data suggests that VSIG4High residential TAMs may
go through high levels of oxidative phosphorylation. In line with this, we observed more mitochondrial
mass and high mitochondria related ROS in CRIg+ TAMs compared with CRIg- TAMs in human
peritoneal ovarian cancer tissues (Supplemental Figure 8H). In addition, we observed that VSIG4High
TAMs were significantly enriched with autophagy associated gene transcripts compared with
VSIG4Low TAMs (Figure 8F), which might be due to the higher arginase-1 activity in CRIg+ TAMs
compared with CRIg- TAMs (Supplemental Figure 8I). Furthermore, high mRNA levels of VSIG4 were
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associated with poor survival (Figure 8G) in patients with ovarian cancer. Altogether, the results
suggest that human ovarian cancer CRIg+ TAMs may be transcriptionally, metabolically, and
functionally similar to the equivalent mouse Tim-4+ TAMs.
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Discussion

Peritoneal residential macrophage subsets are poorly understood in ovarian cancer. Mouse
macrophages are traditionally classified into two subsets: F4/80HighMHC-IILow and F4/80LowMHC-IIHigh.
This classification is arbitrarily based on the relative expression levels of F4/80 and MHC-II. Moreover,
the expression levels of F4/80 and MHC-II are subject to environmental regulation. Hence, this
classification does not serve in sorting specific TAM subsets to study their nature at the transcriptional,
metabolic, and functional levels. To meet this challenge, using murine peritoneal ovarian cancer as a
model, we found that Tim-4 expression explicitly defines two TAM subsets in ovarian cancer bearing
peritoneal cavity: Tim-4+ and Tim-4- cells. Interestingly, Tim-4+ and Tim-4- TAMs are respectively
enriched in F4/80HighMHC-IILow and F4/80LowMHC-IIHigh cells (31, 32). It has been reported that
F4/80HighMHC-IILow and F4/80LowMHC-IIHigh cells are embryonically originated and are peripheral
monocyte-derived cells, respectively (32, 33). Analogously, our complementary and confirmatory
experiments reveal that Tim-4+ TAMs are embryonically originated and locally proliferative cells, while
Tim-4- TAMs are replenished from circulating monocytes. In further support of these findings, it has
been reported that Tim-4 marks certain tissue residential macrophages, including heart, intestine,
skin, and peritoneal cavity (21, 28, 30, 33, 54). Therefore, Tim-4 is a reasonable phenotypic marker to
define TAM subsets in ovarian cancer.

We next explore a potential functional difference between Tim-4+ and Tim-4- TAMs in mouse ovarian
cancer. CC motif ligand 2 (CCL2) and CCR2 signaling pathway mediates peripheral monocyte
trafficking into the tumor microenvironment (55). In line with this, we have observed that the levels of
peritoneal Tim-4- TAMs (monocyte-derived TAM) are reduced in Ccr2 KO mice and in mice treated
with CCR2 antagonist, as compared with controls. However, the reduction of Tim-4- TAMs did not
19

affect peritoneal tumor progression in either Ccr2 KO mice or CCR2 antagonist-treated mice. In
contrast, we found that deletion of Tim-4+ TAMs (embryo derived TAMs) results in reduced peritoneal
tumor progression. In line with this, a recent study has reported a protumor role of omentum
CD163+Tim-4+ TAMs in metastatic ovarian cancer (56). Thus, we suggest that embryo derived TAMs
(Tim-4+) and peripheral monocyte-derived TAMs (Tim-4-) are biologically different in peritoneal ovarian
cancer progression, and specifically targeting Tim-4+ (but not Tim-4-) TAMs may be therapeutically
beneficial to control ovarian cancer and/or other types of cancer peritoneal metastasis and
progression.

In an effort to additionally characterize Tim-4+ and Tim-4+ TAMs, we have examined their major
metabolic profiles. Compared with Tim-4- TAMs, Tim-4+ TAMs presented higher levels of oxidative
phosphorylation, higher levels of all mitochondrial DNA encoded oxidative phosphorylation related
genes, and greater mitochondria mass and ROS production. These data indicate that Tim-4+ TAMs
have experienced high levels of oxidative stress in the tumor microenvironment. In line with this
possibility, Tim-4+ TAMs expressed high levels of active autophagy. To explore the relevance of
autophagy activation in Tim-4+ TAMs, we genetically deleted autophagy gene FIP200 in myeloid cells.
We observed that FIP200 deficiency abrogated peritoneal ovarian cancer progression and improved T
cell-mediated anti-tumor immunity. Accompanied with this, we noticed a loss of Tim-4+ TAMs in
FIP200 deficient mice bearing peritoneal ovarian cancer, but not Tim-4- TAMs. This reinforces a protumor role of Tim-4+ TAMs. In support of this, FIP200 deficiency selectively results in high apoptosis of
Tim-4+ TAMs due to accumulation of damaged mitochondria and mitochondria related ROS. The data
suggest that Tim-4+ TAMs, but not Tim-4- TAMs, rely on mitophagy to survive in the tumor
microenvironment. Interestingly, we found that Tim-4+ TAMs express high levels of arginase-1 and
efficiently convert arginine to downstream metabolites, resulting in limited intracellular arginine.
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Sensing of amino acids, including arginine, causes mTORC1 activation in immune cells (57). In line
with this, we have detected low levels of mTORC1 activity in Tim-4+ TAMs. As mTORC1 is a negative
regulator of classical autophagy through phosphorylating ULK1 (40), this may explain high mitophagy
in Tim-4+ TAMs. Thus, Tim-4+ and Tim-4- TAMs are metabolically programed to have distinct survival
capacities and functions in the tumor microenvironment.

Given that Tim-4 protein is rarely expressed in human ovarian cancer associated macrophages, Tim-4
cannot be used to define human counterparts of mouse Tim-4+ TAM subsets. CRIg (encoded by
Vsig4), a macrophage signature marker, is co-expressed with Tim-4 in mouse F4/80HighMHC-IILow
peritoneal macrophage (21) and Lyve1HighMHC-IILow interstitial macrophage (54). We have explored
CRIg as a potential marker to define human ovarian cancer macrophage subsets. Similar to mouse
Tim-4+ TAMs, transcriptome and functional analysis reveals enriched lysosome related genes,
oxidative phosphorylation pathway, and autophagy pathways in CRIg+ TAMs in human ovarian
cancer. The data suggest that CRIg can be an operational marker to study TAM subsets in human
ovarian cancer. In conclusion, based on Tim-4 (or CRIg in humans), we have identified two
ontogenically, phenotypically, metabolically, and functionally distinct peritoneal macrophage subsets in
ovarian cancer (Graphical abstract). We suggest that specifically targeting human CRIg+ TAMs may
be a meaningful approach for treating peritoneal cancer metastasis.

Methods

Mouse models
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Six- to 8-week old female Cd45.2 C57BL/6 mice (Jackson Laboratory), Cd45.1 C57BL/6 mice
(Jackson Laboratory), Ccr2-/- mice (Jackson Laboratory), LysM-Cre C57BL/6 mice (Jackson
Laboratory), and floxed FIP200 (Fip200flox/flox) C57BL/6 mice (58) were used for this study.
Fip200flox/flox mice (‘Fip200+/+ mice’ here) were intercrossed with LysM-Cre mice to delete the loxPflanked FIP200 alleles specifically in myeloid cells (named ‘Fip200-/- mice’ here). All mice were bred inhouse and maintained in specific pathogen-free conditions. All animal research performed was
approved by the committee on Use and Care of Animals at the University of Michigan. MC38 colon
carcinoma cells and ID8 ovarian cancer cells were used for this work. ID8-luciferase cells (1.5~2 x
106) were injected into the peritoneal cavity of WT mice. Tumor progression was monitored one to two
times per week by Xenogen IVIS® Spectrum in vivo Bioluminescence imaging system (PerkinElmer).
For NAC treatment, four-week Fip200-/- tumor bearing mice were intraperitoneally injected with NAC in
PBS at a dose of 150 mg/kg every other day. Two weeks after NAC treatment, apoptosis of TAMs was
analyzed. For inhibiting monocyte migration, mice were IP injected with 50 µg/kg CCR2 antagonist
(sc-202525, Santa Cruz) every other day for 2 weeks, then pre-treated mice were inoculated with 2 x
106 ID8 tumor cell and continued with CCR2 antagonist injection for 6 weeks.

Human ovarian cancer tissues and ascites

Sixteen patients with high grade serious ovarian cancer were recruited for this study. Ascites,
omentum metastasis, and ovarian cancer tissues were collected from patients with informed consent
according to the procedures approved by the Institutional Review Boards of the University of Michigan
School of Medicine and the Henry Ford Health System. We used clinical samples from people who
had received no prior anticancer therapies. Fresh tumor tissues and ascites were processed into
single-cell suspensions for phenotype and functional studies.
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Isolation of macrophage from the peritoneal cavity

Peritoneal Tim-4+ normal residential macrophages were enriched from 5-8 ml peritoneal elute fluid by
PE-anti-Tim-4 antibody (Clone RMT4-54, BD Bioscience) and anti-PE microbeads (Miltenyi biotec). To
isolate TAM subsets, most tumors cells and dead cells in peritoneal wash of tumor bearing mice were
first removed via density gradient centrifuge by overlying 15 ml single cell suspension on 20 ml of 75%
Ficoll above 15 ml 100% Ficoll. After Ficoll, Tim-4+ TAMs were isolated by using the PE-anti-Tim-4
antibody and anti-PE microbeads (Miltenyi biotec) from collected leukocyte mononuclear cells. Then,
Tim-4- TAMs were enriched from Tim-4- cells through anti-F4/80 MicroBeads UltraPure (Miltenyi
biotec). Total TAMs were enriched from collected leukocyte mononuclear cells through anti-F4/80
MicroBeads UltraPure (Miltenyi biotec). 5 x 105 fresh purified TAMs were directly used for Western
blot and qPCR analysis. In certain experiments, 5 x 105 TAMs were seeded in one well of 24-well
plate for 2 hours, then treated with kinds of inhibitors in complete medium. Medium with/without amino
acids were formulated with RPMI1640 (#R8999-04A, US Biological) by supplementation or omission
of amino acids. The medium was supplemented with 10% (v/v) dialyzed FBS. For flow cytometry,
TAMs were incubated with 500 μl accutase (Life Technologies) for 30 minutes at 37°C, then detached
TAMs were washed and collected for staining.

Macrophage depletion and adoptive transfer

To deplete peritoneal resident macrophages, C57BL/6 mice were treated with 1 dose of clodronatecontaining liposome (100 μl/each). Control mice were treated with same volume of control liposome.
After 2 weeks, mice were intraperitoneally (I.P.) implanted with ID8 tumor cells. For competition
experiments, donor Tim-4+ peritoneal macrophages were isolated from several Fip200-/- CD45.2
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congenic mice and pooled together. Then, 8 x 105 purified cells were immediately admixed with 2 x
106 ID8-luciferase tumor cells and injected (I.P.) into host CD45.1 mouse. 4 weeks later, the cell death
of CD45.1 and CD45.2 TAMs was detected. To explore monocyte-derived macrophages in ID8 tumor
bearing mice, 1 million monocytes were enriched from bone marrow of CD45.1 mice and IP injected
into 4-week tumor bearing mice. Three days later, the phenotype of monocyte derived TAMs was
analyzed by flow cytometry.

Fluorescence-activated cell sorting (FACS) and analysis

Mouse single-cell suspensions were prepared from peripheral blood and from peritoneal cavity, and
blocked with rat anti-mouse CD16/CD32 antibodies (eBioscience) (1/200) for 10 min, pelleted by
centrifugation, and subsequently labeled with fluorophore-conjugated anti-mouse antibodies at
recommended dilutions for 30 minutes in dark room, and washed with staining buffer. To quantitate
the cells, 25 μl CountBright™ absolute counting beads (Thermo Fisher) were added to the samples.
For proliferation assays, mice were injected with 5-bromo-20-deoxyuridine (BrdU, 200 μl/mouse)
(Invitrogene) IP 3 hours prior to sacrifice. Cytofix/cytoperm kit was used to stain for BrdU (BD
Bioscience). For detecting SG2M phase, transcription factor staining buffer set (eBioscience) was used
to stain for Ki67. PBS diluted DAPI (1:1000) was used to stain for the DNA content. To quantitate
blood monocytes, 100 μl of blood was obtained and incubated in red blood cell lysis buffer (BD
Biosciences) for 10 minutes, and stained with fluorophore-conjugated antibodies for 30 minutes in
dark room. For apoptosis, cells were evaluated with an Annexin V apoptosis detection kit (BD
Bioscience). For autophagy quantification in TAM subsets, FlowCellect™ Autophagy LC3 Antibodybased Assay Kit (MilliporeSigma) was used. This kit disrupts the cell plasma membrane and extracts
cytosolic LC-3 by flushing away during washing steps. LC-3 translocated into the autophagosome is
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protected from the extraction and remains intact inside autophagosome, thereby allowing its
fluorescence to be measured by flow cytometry. Events were processed on LSR II and LSRFortessa
flow cytometer (BD Biosciences) and data were analyzed with DIVA software (BD Biosciences). The
antibodies used for flow cytometry were listed in Supplementary Table 2.

Measurement of mitochondria content, mitophagy, and ROS staining

To detect mitochondria activity of fresh TAMs, we first collected leukocyte mononuclear cells from
peritoneal elute cells by density gradient centrifuge. Then, we stained leukocyte mononuclear cells
with macrophage surface antibodies for 30 minutes. Following this, cells were washed and stained
with mitochondria reagents (Life Technologies) for 30 minutes at 37°C in RPMI-1640 without FBS.
MitoTracker Green (100 nM) and MitoTracker Deep red (100 nM) were combined to detect the
mitochondria mass. MitoSOX (5 μM) were used to check mitochondria related ROS. To detected the
effect of arginine on the induced mitophagy, TAMs were treated with oligomycin (10 μM) and
antimycin A (4 μM) (control) in the presence or absence of rapamycin (100 nM). Meanwhile, arginine
or argininse-1 inhibitor, Nor-NOHA (0.5 mM, Nor-NOHA) was added into the culture for 24 hours. The
levels of damaged mitochondria without any inhibitors were used as background control. The
percentages of accumulated damaged mitochondria were normalized to control group. After washing
with PBS for 2 times, the stained TAMs were gated and detected via BD LSR flow cytometry.

Extracellular flux analysis

Analysis of the oxygen consumption rate (OCR) was performed with a Seahorse XF96 Extracellular
Flux Analyzer instrument. Sorted TAM subsets were seeded at 2 x 105 per well (96-well) in RPMI25

1640 with 10% FBS and incubated for 1 to 2 hours. The media were removed and replaced with
Seahorse assay media with 2 mM glutamine and 25 mM glucose. The plates containing cells were
incubated for 1 hour at 37°C without CO2. Extracellular flux analysis was performed at 37°C without
CO2 in the XF-96 analyzer (Seahorse Bioscience) following the manufacturer’s instructions. Port
additions and times are indicated in the Figure.s. Oligomycin (1.25 μM), FCCP (0.5 μM) and rotenone
(1 μM) plus antimycin A (1 μM) were injected where related, and OCR (pMoles O2/min) were
measured in real time.

Arginine uptake and arginase activity assay

To detect the arginine uptake in TAM subsets, 5 x 105 TAMs were seeded in 24-well plate for 24
hours. Then, culture media with or without TAMs were collected to detect the arginine amount with the
L-arginine assay kit (BioVision). The levels of arginine uptake were determined by using the amount of
arginine in culture medium without TAMs to subtract the amount of arginine in culture medium with
TAMs. To detect the arginase activity in TAM subsets, 5 x 105 fresh TAMs were lysed in 10 mM TrisHCL 7.4 buffer containing 0.4% (W/V) Triton-X-100 and protease inhibitors. The arginase activity was
measured by the Arginase Assay Kit (Abnova). The lysed cells were centrifuged at 14,000 g at 4 °C
for 10 minutes, and the supernatants were plated on to a 96-well microtiter plate. L-arginine was
converted to urea by a buffer containing a substrate and cofactor, and the absorbance of the samples
was measured using a microplate reader at the wavelength of 430 nm.

Real-time PCR and RNA sequencing analysis

Total RNA was isolated from cells by column purification (Direct-zol RNA Miniprep Kit, Zymo
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Research) with DNase treatment. cDNA was synthesized using High-Capacity cDNA Reverse
Transcription Kit (Thermo Fisher Scientific) with poly-dT or random hexamer primers. Quantitative
PCR (qPCR) was performed on cDNA using Fast SYBR Green Master Mix (Thermo Fisher Scientific)
on a StepOnePlus Real-Time PCR System (Thermo Fisher Scientific). Fold changes in mRNA
expression were calculated by the ΔΔCt method using Actb as an endogenous control. Results are
expressed as fold change by normalizing to the controls. The primers used for qPCR were listed in
Supplementary Table 2. The acquisition and analysis of RNA sequencing data was described
previously (59). Total RNA was isolated from cells by column purification (Direct-zol RNA Miniprep Kit,
Zymo Research) with DNase treatment. The Ribo-Zero Gold rRNA Removal Kit (Illumina) and TruSeq
Stranded Total RNA Library Prep Globin kit (Illumina) were used to prepare the library for RNA
sequencing. Sequencing was performed by the University of Michigan DNA Sequencing Core, using
the Illumina Hi-Seq 4000 platform, paired end, 50 cycles. Quality of the raw reads data for each
sample was first evaluated using FastQC (version 0.11.3). The Tuxedo Suite software package was
used for alignment, differential expression analysis, and post-analysis diagnostics. In brief, reads were
aligned to the reference transcriptome (hg19) using TopHat (version 2.0.13) and a second round of
quality control was performed after alignment. Cufflinks/CuffDiff (version 2.2.1) was used for
expression quantification, normalization, and differential expression analysis. Locally developed
scripts were used to format and annotate the differential expression data output from CuffDiff.
Diagnostic plots were generated using the CummeRbund R package.

Western blot

Cells were dissolved in RIPA Lysis and extraction buffer (Thermo Fisher Scientific) supplemented with
protease inhibitor cocktail (Roche). The protein concentrations were determined by Bio-Rad protein
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assay reagent. The lysates were boiled for 5 minutes in 3 x SDS sample buffer (0.5 M Tris-HCl, pH
6.8, 30% glycerol, 3% SDS, 0.01% bromphenol blue) containing 3% β-mercaptoethanol, and were
analyzed by SDS-PAGE followed by Western blot using different antibodies; including Arginase-1
(93668, Cell Signaling), Arginase-2 (55003, Cell Signaling), CDK4 (11026-1-AP, Proteintech), CDK6
(3136, Cell Signaling), Cleaved Caspase-3 (Asp175) (9661, Cell Signaling), COX IV (4844, Cell
Signaling), Cyclin D1 (2922, Cell Signaling), Cyclin D3 (2936, Cell Signaling), FIP200 (17250-1-AP,
Proteintech), LC3A/B (12741, Cell Signaling), Phospho-Histone H2A.X (Ser139) (9718, Cell
Signaling), Phospho-p70 S6 kinase (Thr389) (9205, Cell Signaling), Phospho-S6 (Ser235/236) (4858,
Cell Signaling), Phospho-ULK1 (Ser317) (12753, Cell Signaling), Phospho-ULK1 (Ser757) (14202,
Cell Signaling), SDHB (ab14714, Abcam), SQSTM1/p62 (5114, Cell Signaling), ULK1 (8054, Cell
Signaling), and β-Actin (A5441, Sigma). Signals were detected by ECL reagents (Thermo Fisher
Scientific). The protein expression levels were quantified with ImageJ software and were normalized to
1 in specific control groups.

Enrichment and gene ontology analysis

Gene set enrichment analysis was performed using the GSEA software downloaded from Broad
Institute (60). The gene signatures for GSEA were listed in Supplementary Table 2. The function was
used to compute the enrichment scores and simulated enrichment scores for each variable and
signature. A comprehensive gene set enrichment analysis web server Enrichr (61) was used for
KEGG pathway and gene ontology analysis in human TAMs. Important KEGG pathways and GO
terms were selected.

Statistical analysis
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Mann-Whitney U test was used to compare two independent groups. Student’s t-test was used for
paired samples. The Pearson's correlation was used to analyze the association between two
continuous variables. For multigroup comparisons, one-way ANOVA with Dunnett’s multiple
comparisons test was utilized to identify group-specific differences. Statistical analysis was performed
with GraphPad Prism 8 software (GraphPad Software, Inc.). P < 0.05 was considered significant.
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Figure Legends

Figure 1. Tim-4 defines two distinct peritoneal macrophage subsets in ovarian cancer. (A) Measurement of
macrophage related markers on TAMs. CD45+CD11b+B220-CD90-Gr1- macrophages were identified in peritoneal single
cells in mice bearing peritoneal ID8 ovarian cancer (n = 10). (B), Dynamic changes of peritoneal TAMs during ID8
peritoneal ovarian cancer progression (n =10 to14/group, mean ± SEM). ****P < 0.0001 (one-way ANOVA with Dunnett’s
multiple comparisons test) between tumor-free and tumor bearing mice. Time points: 2-4, 4-6, and 6-8 weeks. (C)
Representative surface expression of Tim-4 on peritoneal TAMs. Data are shown at week 4 after ovarian cancer
inoculation (n = 10). (D) Phenotypic difference in Tim-4+ and Tim-4- TAMs. TAMs were stained with the indicated
antibodies. One representative of 5 is shown. (E) Transcripts in TAM subsets. Peritoneal TAMs subsets were isolated and
sorted from 6 to 7 weeks in ID8 tumor bearing mice. An RNA sequencing assay was performed in 4 groups of paired Tim4+ and Tim-4- TAMs. Volcano plots show up-regulated and down-regulated genes based on statistic value P < 0.05 and
fold change ≥ 2 or ≤ -2. (F and G) RNA-Seq analysis in TAMs. Positive gene enrichment of residential macrophage gene
signatures (F) and negative gene enrichment of MHC-II+ macrophage gene signatures (G) in Tim-4+ TAMs compared with
Tim-4- TAMs. The 20 most enriched genes are shown on the right side. Normalized enrichment score (NES), false
discovery rate (FDR). FDR < 0.25 is considered significant.
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Figure 2. Tim-4- TAMs migrate from peripheral monocytes without affecting tumor growth. (A and B) Dynamic
changes of Tim-4+ (A) and Tim-4- (B) TAM numbers during peritoneal ovarian cancer progression (n = 5 to 14 mice/group,
mean ± SEM). ***P < 0.001, ****P < 0.0001 (one-way ANOVA with Dunnett’s multiple comparisons test) between tumorfree and tumor-bearing mice at different time points. (C) Tumor growth in mice treated with CCR2 antagonist or PBS (n = 8
to 10 mice/group, mean ± SEM). (D) Tim-4+ TAM numbers in mice treated with CCR2 antagonist or PBS (n = 4 to 5
mice/group, mean ± SEM). (E) ID8 tumor growth in Ccr2+/+ and Ccr2-/- mice (n = 5 mice/group, mean ± SEM). (F and G)
Effect of CCR2 deficiency on Tim-4- TAMs. Percentage (F) and number (G) of Tim-4- TAMs were compared between
Ccr2+/+ and Ccr2-/- mice bearing ID8 tumors. (n = 5 mice/group, mean ± SEM). * P < 0.05, ** P < 0.01 (Mann-Whitney U
tests). (H) Source of Tim-4+ TAMs. CD45.1+ monocytes were transferred (I.P) into ID8 tumor bearing CD45.2 mice. Tim-4
was determined on CD45.1+ (red) and CD45.2+ (blue) TAMs. One representative of 4 is shown.
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Figure 3. Tim-4+ TAMs are embryonically derived proliferative cells with pro-tumor function. (A and B) Proliferative
status of Tim-4+ TAMs in tumor bearing mice. (A) Flow cytometry dot plots represent the percentage of Tim-4+
macrophages in SG2M phase. (B) Percentage of SG2M positive macrophages in Tim-4+ peritoneal macrophages from
normal and ID8 bearing mice (n = 10-12 mice/group, mean ± SEM). **** P < 0.0001 (Mann-Whitney U tests). (C) Western
blot showing cell cycle proteins in Tim-4+ peritoneal residential macrophages and Tim-4+ TAMs. One representative of 3 is
shown. (D) Effect of clodronate liposome on peritoneal macrophages (PMs). Tim-4+ and Tim-4- peritoneal macrophage
numbers were quantified in tumor free mice treated with control liposome or clodronate liposome (n = 4 mice/group, mean
± SEM). * P < 0.05 (Mann-Whitney U tests) between control and clodronate treated mice in both Tim-4+ PMs and Tim-4PMs. (E) Tumor growth between control liposome and clodronate liposome pre-treated mice (n = 6-8 mice/group, mean ±
SEM). * P < 0.05 (Mann-Whitney U tests) between control and clodronate treated mice at day 12, 26, and 39. (F)
Percentage of TAM subsets in total CD45+ immune cells between control and clodronate treatment (n = 6-7 mice/group,
mean ± SEM). ** P < 0.01 (Mann-Whitney U tests) between control and clodronate treated mice. (G) The Pearson’s
correlation between Tim-4+ TAM numbers and tumor load. Red line indicates regression fit.
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Figure 4. Tim-4+ TAMs exhibit and maintain high mitochondria activity and autophagy function. (A and B) Oxygen
consumption rates (OCR) in TAM subsets. Peritoneal TAM subsets were sorted from ID8 tumor bearing mice and treated
with oligomycin (Oligo), FCCP, and rotenone plus antimycin A (R/AA). (A) OCR was determined by using the XF
Extracellular Flux Analyzer in Tim-4+ and Tim-4- TAMs. Basal and maximal respiration was shown. (n = 6 mice/group,
mean ± SEM). * P < 0.05, ** P < 0.01 (Paired t- tests). (B) Percentage of OCR was normalized to basal level in Tim-4+
TAMs and Tim-4- TAMs. (n = 6 mice/group, mean ± SEM). * P < 0.05 (Mann-Whitney U tests) between Tim-4+ TAMs and
Tim-4- TAMs at the indicated time point. (C) Measurement of mitochondria related ROS in Tim-4+ and Tim-4- TAMs (n = 11
mice/group, mean ± SEM). ** P < 0.01 (Mann-Whitney U tests). (D) Positive enrichment of the mitochondrial DNA encoded
OXPHOS related genes in Tim-4+ TAMs compared with Tim-4- TAMs. ES plots (left panel); 13 enriched genes (right
panel). Normalized enrichment score (NES), false discovery rate (FDR). FDR < 0.25 is considered significant. (E)
Mitochondrial mass of Tim-4+ and Tim-4- TAMs (n = 5 mice/group, mean ± SEM). * P < 0.05 (Mann-Whitney U tests). (F)
Measurement of LC-3II density in autophagosome between Tim-4+ and Tim-4- TAMs (n = 7 mice/group). The paired Tim4+ and Tim-4- TAMs were from the same mice. *** P < 0.001 (Mann-Whitney U tests). (G) Flow cytometry dot plots
showing the percentage of damaged mitochondria in TAM subsets treated with or without CQ for 24 hours. The difference
between CQ treatment and control was considered accumulated damaged mitochondria in Tim-4+ TAMs and Tim-4- TAMs.
(n = 4 mice/group, mean ± SEM). * P < 0.05 (Mann-Whitney U tests).
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Figure 5. Arginase-1 impacts mitochondria fitness and mitophagy via mTORC1 in Tim-4+ TAMs. (A) Western blot
showing mTORC1 activity in fresh Tim-4+ TAMs and Tim-4- TAMs. One representative of 3 is shown. (B) Western blot
showing mTORC1 activity in Tim-4+ TAMs and Tim-4- TAMs. TAMs were isolated from tumor bearing mice and cultured
overnight in completed medium. TAMs were stimulated in amino-acid free (-AA) medium or full amino acids medium (+AA)
for 4 hours. One representative of 3 is shown. (C) Western blot showing mTORC1 activity in Tim-4+ TAMs treated with
arginine for 24 hours. One representative of 3 is shown. (D) Measurement of arginase-1 expression in Tim-4+ TAMs and
Tim-4- TAMs by flow cytometry. The paired Tim-4+ and Tim-4- TAMs were from the same mouse. (n = 7 mice/group). * P <
0.05 (Mann-Whitney U tests). (E) Measurement of arginase activity Tim-4+ TAMs and Tim-4- TAMs by ELISA. The paired
Tim-4+ and Tim-4- TAMs were from the same mice. (n = 4 mice/group). * P < 0.05 (Mann-Whitney U tests). (F) Western
blot showing mTORC1 activity in Tim-4+ TAMs treated with arginase inhibitor, Nor-NOHA (0.5 mM), for 24 hours. One
representative of 3 is shown. (G) Effect of arginine on damaged mitochondria accumulation (mitophagy) in Tim-4+ TAMs.
In the absence or presence of rapamycin, mitochondria damage was induced as described in Tim-4+ TAMs without
(control), or with arginine (arginine), or arginase-1 inhibitor Nor-NOHA (Nor-NOHA). Damaged mitochondria accumulation
was determined by FACS. Results were normalized to control. (n = 4 mice/group, mean ± SEM). *** P < 0.001, **** P <
0.0001 (one-way ANOVA with Dunnett’s multiple comparisons test).
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Figure 6. Autophagy deficiency results in loss of Tim-4+ TAMs in ovarian cancer. (A) Effect of FIP200 deficiency on
mitochondria in Tim-4+ TAMs and Tim-4- TAMs. The percentage of Tim-4+ TAMs and Tim-4- TAMs with damaged
mitochondria in Fip200+/+ and Fip200-/- tumor bearing mice. (n = 8 mice/group, mean ± SEM). *** P < 0.001 (Mann-Whitney
U tests). (B and C) Percentage (B) and number (C) of TAMs in total immune cells between Fip200+/+ and Fip200-/- tumor
bearing mice (n = 5 to 8 mice/group, mean ± SEM). * P < 0.05; ** P < 0.01 (Mann-Whitney U tests). (D and E) Percentage
(D) and number (E) of Tim-4+ and Tim-4- TAM subsets in total immune cells between Fip200+/+ and Fip200-/- tumor bearing
mice (n=11 mice/group, mean ± SEM). *** P < 0.001; **** P < 0.0001 (Mann-Whitney U tests) in Tim-4+ TAMs between
Fip200+/+ and Fip200-/-. (F) Apoptosis of Tim-4+ TAMs in Fip200+/+ and Fip200-/- tumor bearing mice. (n = 6 mice/group,
mean ± SEM). ** P < 0.01 (Mann-Whitney U tests). (G) Effect of FIP200 deficiency on Tim-4+ TAM apoptosis. TAMs were
analyzed for apoptosis 36 days after tumor inoculation (n = 5 mice/group). ** P < 0.01 (Mann-Whitney U tests). (H)
Measurement of mitochondria related ROS in Tim-4+ TAMs between Fip200+/+ and Fip200-/- tumor bearing mice (n = 4
mice/group, mean ± SEM). * P < 0.05 (Mann-Whitney U tests). (I) Effect of NAC on Tim-4+ TAM apoptosis in vivo (n = 4
mice/group, mean ± SEM). * P < 0.05 (Mann-Whitney U tests). (J) Comparison of apoptosis between paired Tim-4+ and
Tim-4- TAMs in Fip200-/- tumor bearing mice (n = 6 mice/group). ** P < 0.01 between Tim-4+ versus Tim-4- TAMs in
Fip200-/- tumor bearing mice (Mann-Whitney U tests). (K) Mitochondrial ROS ratio of Fip200-/- versus Fip200+/+ in TAMs
subsets (n = 4 mice/group, mean ± SEM). * P < 0.05 (Mann-Whitney U tests).
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Figure 7. Autophagy deficiency in macrophages supports T cell-mediated anti-tumor immunity. (A) Effect of FIP200
deficiency on peritoneal ovarian cancer progression. Wild type (Fip200+/+) and FIP200 deficient (Fip200-/-) mice were (I.P)
injected with ID8 tumor cells. Tumor growth was monitored (n = 6 to 8 mice/group, mean ± SEM). * P < 0.05, ** P < 0.01
(Mann-Whitney U tests) between Fip200+/+ and Fip200-/- tumor bearing mice. (B) Percentage of T cells in total immune
cells between Fip200+/+ and Fip200-/- tumor bearing mice (n = 11 mice/group, mean ± SEM). * P < 0.05 (Mann-Whitney U
tests). (C) Percentage of Ki67 positive T cells between Fip200+/+ and Fip200-/- tumor bearing mice (n = 4 mice/group, mean
± SEM). * P < 0.05 (Mann-Whitney U tests). (D and E) Percentage of IFNγ+ (D) and TNFα+ (E) T cell subsets in Fip200+/+
and Fip200-/- tumor bearing mice (n = 5 mice/group, mean ± SEM). ** P < 0.01 (Mann-Whitney U tests) in both CD4+ and
CD8+ T cells.
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Figure 8. CRIg+ TAMs are the murine counterparts of Tim-4+ TAMs in human ovarian cancer. (A-F) Signaling
pathway analysis in human ovarian cancer TAM subsets. Based on VSIG4 transcript levels in the RNA-Seq dataset (25),
ovarian cancer ascites TAMs were divided into VSIG4High and VSIG4Low groups. The VSIG4High group included top 4 higher
VSIG4 expressing TAMs (sample#: TAM43, TAM69, TAM72, and TAM105), while the VSIG4Low group included bottom 4
lower VSIG4 expressing TAMs (sample#: TAM31, TAM92, TAM108, and TAM117). (A) Principle component analysis
(PCA) plot of 13,778 genes expressed in VSIG4High and VSIG4Low TAMs. (B and C) Gene set enrichment in human
CRIgHigh macrophages and VSIG4High TAMs. The significantly up-regulated or down-regulated genes (FC ≥ 2 or ≤ -2, P <
0.05) were determined in human CRIgHigh macrophages as compared with CRIgLow macrophages, and in VSIG4High TAMs
as compared with VSIG4Low TAMs. Positive enrichment of up-regulated gene set in human CRIgHigh macrophages and
VSIG4High TAMs is shown (B). Negative enrichment of down-regulated gene set in human CRIgHigh macrophage and
VSIG4High TAMs is shown (C). Normalized enrichment score (NES), false discovery rate (FDR). (D-F) Enrichment of
several pathways (D), oxidative phosphorylation gene (E), and autophagy gene (F) sets in VSIG4High TAMs compared with
VSIG4Low TAMs. Normalized enrichment score (NES), false discovery rate (FDR). FDR < 0.25 is considered significant.
(G) Ovarian cancer patients were divided into high (16 patients) and low (39 patients) VSIG4 expression groups. Patient
survival was shown based on VSIG4 transcript levels. FDR < 0.25 is considered significant.
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